首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1378549

胆管癌市场：依癌症类型、治疗类型、给药途径、配销通路及地区分类

Cholangiocarcinoma Market, By Cancer Type, By Therapy Type, By Route of Administration, By Distribution Channel, and By Region

出版日期: 2023年10月20日 | 出版商:

Coherent Market Insights | 英文 156 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计2023年全球胆管癌市场规模为4.232亿美元，预计到2030年将达到160.7万美元，在预测期内（2023-2030年）年度增长20.9%，预计呈现平均增长率（年复合成长率）。

报告范围		报告详情
基准年	2022年	2023年市场规模	4.232 亿美元
实绩资料	2018-2021	预测期	2023-2030
预测期年复合成长率	20.90%	2030年市场规模预测	16.7亿美元

图 1. 2023 年按治疗类型分類的胆管癌全球市场占有率(%)

胆管癌，也称为胆管癌，是一种始于胆管的癌症。胆管癌是一种比较罕见的癌症，而且癌症的症状往往要到晚期才会出现，所以必须在阶段才被诊断出来。胆管癌的确切病因尚不清楚，但胆管慢性发炎、某些感染疾病（如肝流感寄生虫）和某些危险因子（如吸烟和酗酒）等因素可能导致这种癌症。它被认为会增加发育风险。诊断通常涉及影像检查（例如电脑断层扫描、MRI 或内视镜逆行性胰造影(ERCP)）与组织切片检查的结合，以确认癌症的存在。胆管癌的治疗方法根据癌症的阶段和患者的一般状况而有所不同。治疗方法包括手术、放射线治疗、化疗和其他标靶治疗。胆管癌的预后因诊断阶段而异，早期发现和介入对于改善预后至关重要。

市场动态

主要企业正在进行研发活动，预计这将在预测期内推动全球胆管癌市场的成长。例如，2022 年 2 月，德国临床研究机构 Krankenhaus Nordwest 的 Institut Fur Klinische Krebsforschung IKF GmbH 宣布「durvalumab 和 tremelimumab 联合或不联合卡培他滨用于胆道癌的辅助性治疗」。名为「第二阶段免疫疗法试验”的临床试验。该研究目前处于第二阶段，预计将于 2024 年 12 月完成。

本次测试的主要特点

本报告详细分析了全球胆管癌市场，并提供了以2022年为基准年的预测期（2023-2030）的市场规模和年复合成长率(CAGR)。
它还阐明了不同细分市场的潜在商机，并解释了该市场有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
它根据公司亮点、产品系列、主要亮点、绩效和策略等参数，介绍了全球胆管癌市场的主要企业。
该报告的见解将使行销人员和公司负责人能够就未来的产品发布、类型升级、市场经营团队和行销策略做出资讯的决策。
全球胆管癌市场报告迎合了该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
透过用于分析全球胆管癌市场的各种策略矩阵，将有助于相关人员做出决策。

公司简介
- BridgeBio Inc.
- Sanofi
- Eisai Co., Ltd.
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Intas Pharmaceuticals Ltd.
- Fresenius SE &Co. KGaA
- Sun Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals PLC
- Incyte
- TRISALUS LIFE SCIENCES, INC.
- GENFIT
- Johnson &Johnson Private Limited
- Bliss Biopharmaceutical
- Novartis AG
- LES LABORATOIRES SERVIER
- F.Hoffmann-La Roche Ltd
- Mylan NV（Viatris.Inc）
- AstraZeneca
- Compass Therapeutics, Inc
- Otsuka Holdings Co., Ltd.
- Senhwa Biosciences, Inc.
分析师观点

第11章章节

参考
调查方法

简介目录

Product Code: CMI4435

Global Cholangiocarcinoma market is estimated to be valued at US$ 423.2 Mn in 2023 and is expected to reach US$ 1,600.7 Mn by 2030, exhibiting a Compounded Annual Growth Rate (CAGR) of 20.9% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 423.2 Mn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	20.90%	2030 Value Projection:	US$ 1,600.7 Mn

Figure 1. Global Cholangiocarcinoma Market Share (%), By Therapy Type, 2023

Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that originates in the bile ducts. Cholangiocarcinoma is a relatively rare cancer which needs to be diagnosed at an advanced stage because the symptoms of the cancer often appears late until the disease is at its well-advanced stage. The exact cause of cholangiocarcinoma is unknown, but it is believed that factors such as chronic inflammation of the bile ducts, certain infections (e.g., with the liver fluke parasite), and certain risk factors (e.g., smoking, heavy alcohol use) may increase the risk of developing this cancer. Diagnosis typically involves a combination of imaging studies, such as CT scans, MRIs, and endoscopic retrograde cholangiopancreatography (ERCP), as well as tissue biopsies to confirm the presence of cancer. Treatment options for cholangiocarcinoma depends on the stage of the cancer and the patient's overall health. The treatments are surgery, radiation therapy, chemotherapy, and other targeted therapies. Prognosis for cholangiocarcinoma varies depending on the stage at which it is diagnosed, and early detection and intervention are crucial for improving outcomes.

Market Dynamics

Key players are engaged in research and development activities which is expected to drive the global cholangiocarcinoma market growth over the forecast period. For instance, in February 2022, Institut fur Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, a Germany-based clinical research institution, initiated a clinical trial titled "A Phase II Study of Immunotherapy with Durvalumab and Tremelimumab in Combination with Capecitabine or Without Capecitabine in Adjuvant Situation for Biliary Tract Cancer". The study is currently in phase 2 which is estimated to get completed by December 2024.

Key features of the study:

This report provides an in-depth analysis of the global cholangiocarcinoma market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global cholangiocarcinoma market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include BridgeBio Inc., Sanofi, Eisai Co., Ltd., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Fresenius SE & Co. KGaA, Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Incyte, TRISALUS LIFE SCIENCES, INC., GENFIT, Johnson & Johnson Private Limited, Bliss Biopharmaceutical, Novartis AG, LES LABORATOIRES SERVIER, F. Hoffmann-La Roche Ltd, Mylan N.V. (Viatris.Inc), AstraZeneca, Compass Therapeutics, Inc, Otsuka Holdings Co., Ltd., and Senhwa Biosciences, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global cholangiocarcinoma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cholangiocarcinoma market

Detailed Segmentation:

Global Cholangiocarcinoma Market, By Cancer Type:
- Perihilar
- Distal
- Extrahepatic Cholangiocarcinoma
- Intrahepatic Cholangiocarcinoma
Global Cholangiocarcinoma Market, By Therapy Type:
- Targeted Drug Therapy
- Pemigatinib
- Ivosidenib
- Futibatinib
- Infigratinib
- Chemotherapy
- 5-fluorouracil
- Gemcitabine
- Cisplatin
- Capecitabine
- Oxaliplatin
- Immunotherapy
- Pembrolizumab
- Others (Late phase pipeline drugs)
- Others (Pain Medications and others)
By Route of Administration:
- Oral
- Subcutaneous
- Intravenous
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- E-commerce
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Company Profiles
- BridgeBio Inc.
- Sanofi
- Eisai Co., Ltd.
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Intas Pharmaceuticals Ltd.
- Fresenius SE & Co. KGaA
- Sun Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals PLC
- Incyte
- TRISALUS LIFE SCIENCES, INC.
- GENFIT
- Johnson & Johnson Private Limited
- Novartis AG
- LES LABORATOIRES SERVIER
- F. Hoffmann-La Roche Ltd
- Mylan N.V. (Viatris.Inc)
- AstraZeneca
- Compass Therapeutics, Inc
- Otsuka Holdings Co., Ltd.
- Senhwa Biosciences, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Cancer Type
- Market Snippet, By Therapy Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Recent Product Launches/Approvals
Recent Trends
Mergers, Acquisitions, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis
PORTER's Analysis

4. Global Cholangiocarcinoma Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Cholangiocarcinoma Market, By Cancer Type, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Extrahepatic Cholangiocarcinoma
Perihilar
Distal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
Intrahepatic Cholangiocarcinoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends

6. Global Cholangiocarcinoma Market, By Therapy Type, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Targeted Drug Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
Pemigatinib
Ivosidenib
Futibatinib
Infigratinib
Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
5- fluorouracil
Gemcitabine
Cisplatin
Capecitabine
Oxaliplatin
Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
Pembrolizumab
Others (Late phase pipeline drugs)
Others (Pain Medications and others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends

7. Global Cholangiocarcinoma Market, By Route of Administration, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Oral
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Subcutaneous
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Intravenous
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends

8. Global Cholangiocarcinoma Market, By Distribution Channel, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
E-commerce
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

9. Global Cholangiocarcinoma Market, By Region, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and By Y-o-Y Growth, By Region, 2018 - 2030, (US$ Mn)
North Africa
Central Africa
South Africa

10. Competitive Landscape

Company Profiles
- BridgeBio Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Sanofi
- Eisai Co., Ltd.
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Intas Pharmaceuticals Ltd.
- Fresenius SE & Co. KGaA
- Sun Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals PLC
- Incyte
- TRISALUS LIFE SCIENCES, INC.
- GENFIT
- Johnson & Johnson Private Limited
- Bliss Biopharmaceutical
- Novartis AG
- LES LABORATOIRES SERVIER
- F.Hoffmann-La Roche Ltd
- Mylan N.V. (Viatris.Inc)
- AstraZeneca
- Compass Therapeutics, Inc
- Otsuka Holdings Co., Ltd.
- Senhwa Biosciences, Inc.
Analysts' Views

11. Section

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

胆管癌市场：依癌症类型、治疗类型、给药途径、配销通路及地区分类

Cholangiocarcinoma Market, By Cancer Type, By Therapy Type, By Route of Administration, By Distribution Channel, and By Region

图 1. 2023 年按治疗类型分類的胆管癌全球市场占有率(%)

市场动态

本次测试的主要特点

目录

第1章调查目的和假设

第2章市场展望

第3章市场动态、法规及趋势分析

第4章全球胆管癌市场-COVID-19感染疾病的影响分析

第5章全球胆管癌市场，依癌症类型，2018-2030

第6章全球胆管癌市场，依治疗类型，2018-2030

第7章全球胆管癌市场，依给药途径，2018-2030

第8章全球胆管癌市场，依配销通路，2018-2030

第9章2018-2030年全球胆管癌市场（按地区）

第10章竞争形势